Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Construction in Progress (2016 - 2019)

Lineage Cell Therapeutics' Construction in Progress history spans 6 years, with the latest figure at $8.9 million for Q1 2019.

  • For Q1 2019, Construction in Progress changed N/A year-over-year to $8.9 million; the TTM value through Mar 2019 reached $8.9 million, changed N/A, while the annual FY2018 figure was $1.3 million, 77.08% down from the prior year.
  • Construction in Progress reached $8.9 million in Q1 2019 per LCTX's latest filing, up from $1.3 million in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $8.9 million in Q1 2019 to a low of $93000.0 in Q4 2015.
  • Average Construction in Progress over 5 years is $3.1 million, with a median of $1.6 million recorded in 2016.
  • Peak YoY movement for Construction in Progress: crashed 77.09% in 2015, then skyrocketed 117.26% in 2016.
  • A 5-year view of Construction in Progress shows it stood at $93000.0 in 2015, then skyrocketed by 1620.43% to $1.6 million in 2016, then soared by 245.81% to $5.5 million in 2017, then tumbled by 77.08% to $1.3 million in 2018, then surged by 603.31% to $8.9 million in 2019.
  • Per Business Quant, the three most recent readings for LCTX's Construction in Progress are $8.9 million (Q1 2019), $1.3 million (Q4 2018), and $5.1 million (Q3 2018).